Information Provided By: 
Fly News Breaks for March 5, 2019
EVOK
Mar 5, 2019 | 07:08 EDT
H.C. Wainwright analyst Raghuram Selvaraju downgraded Evoke Pharma to Neutral without a price target after the company disclosed the receipt of a multi-disciplinary review letter from the FDA on its New Drug Application for Gimoti. The issues raised in the letter are concerning, Selvaraju tells investors in a research note. All at least imply significant delays to approval, says the analyst.
News For EVOK From the Last 2 Days
EVOK
Apr 24, 2024 | 10:47 EDT
